Figure 3From: Proinflammatory and prothrombotic effects on human vascular endothelial cells of Immune-cell-derived LIGHT A-3B, Matrix metalloproteinase (GM6001) mediates shedding of soluble LIGHT. 30 minutes prior to activation of PBL and CD4+ subsets with PMA metalloproteinase inhibitor GM6001 (30 μM) was added to the medium. After 24 hours and 48 hours the conditioned medium was analyzed for the presence of soluble LIGHT by ELISA. MMP inhibitor markedly reduced the release of soluble LIGHT in lymphocytes (Figure 3A and 3B). Values represent the mean ± SD of soluble LIGHT analyzed in triplicate. ***P < 0.0005 vs without GM6001 treated cells.Back to article page